Second Bio Lab Clinical Laboratory

Second Bio Lab Clinical Laboratory was paid $160K by Medicaid between Mar 2022 and Oct 2024, across 13 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#298 of 561

Median peer was paid$222K

This provider vs. median0.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	1,747	$72K
2023	2,124	$68K
2024incomplete	5,272	$20K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	53%	1,202	633	$85K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	15%	1,150	592	$24K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	11%	911	331	$18K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	8.4%	608	296	$13K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	7.5%	1,195	984	$12K
87481		2.7%	1,197	990	$4K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	573	572	$2K
87150		<1%	456	455	$829.84
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	710	687	$587.25
87640		<1%	553	551	$426.67
87653		<1%	563	561	$357.11
87498		<1%	13	13	$89.83

1 more codes

87502

Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets

<1%

12

$68.98

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialORUE-PEREA, GABRIELA (OWNER)